Investigational drug · Phase 2
BW-20805
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hereditary Angioedema (HAE).
Phase 2Last checked: Nov 20, 2026Latest source record: Apr 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "BW-20805"
First trial start
2025
Feb 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BW-20805", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hereditary Angioedema (HAE)
Approved drugs for the same conditions: Hereditary angioedema · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "BW-20805" as an intervention, largest first.
- A Phase 2 in Adult Subjects With Hereditary AngioedemaActive, not recruiting
Shanghai Argo Biopharmaceutical Co., Ltd.Industry
NCT06846398 · 25 participants · Start Feb 28, 2025 · Primary completion Jun 30, 2026
Drug: BW-20805; BW-20805 and 1 more · For: Hereditary Angioedema (HAE)
Sites: Silver Spring, Maryland; St Louis, Missouri; Durham, North Carolina · 18 sites in all
- A Phase 1 Clinical Study of BW-20805-2-1001 in Healthy ParticipantsNot yet recruiting
Shanghai Argo Biopharmaceutical Co., Ltd.Industry
NCT07528053 · 24 participants (planned) · Start Apr 28, 2026 · Primary completion Jun 30, 2026
Drug: BW-20805; BW-20805 and 1 more · For: HV
Sites: Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Landscape of hereditary angioedema in China: A multicenter cross-sectional questionnaire survey.
Xu Y, Chen W, Craig T, et al. · World Allergy Organ J 2026
Also in development for Hereditary Angioedema (HAE)
- siRNAADX-038, ADX-324Phase 37 trials
ADARx Pharmaceuticals, Inc. · Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1
- DeucrictibantPHVS416, PHA121Phase 35 trials
Pharvaris Netherlands B.V. · Hereditary Angioedema (HAE), Hereditary Angioedema, Hereditary Angioedema Type I
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.